1. A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE). Issue 181 (September 2019) Authors: Ten Cate, V.; Koeck, T.; Panova-Noeva, M.; Rapp, S.; Prochaska, J.H.; Lenz, M.; Schulz, A.; Eggebrecht, L.; Hermanns, M.I.; Heitmeier, S.; Krahn, T.; Laux, V.; Münzel, T.; Leineweber, K.; Konstantinides, S.V.; Wild, P.S. Journal: Thrombosis research Issue: Issue 181(2019) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor‐induced hypercoagulability in vitro and in vivo. (19th June 2014) Authors: Perzborn, E.; Heitmeier, S.; Buetehorn, U.; Laux, V. Journal: Journal of thrombosis and haemostasis Issue: Volume 12:Number 7(2014:Jul.) Page Start: 1054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A. (29th January 2014) Authors: Gu, J‐M.; Ramsey, P.; Evans, V.; Tang, L.; Apeler, H.; Leong, L.; Murphy, J. E.; Laux, V.; Myles, T. Journal: Haemophilia Issue: Volume 20:Number 4(2014:Jul.) Page Start: 593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A. (29th January 2014) Authors: Gu, J‐M.; Ramsey, P.; Evans, V.; Tang, L.; Apeler, H.; Leong, L.; Murphy, J. E.; Laux, V.; Myles, T. Journal: Haemophilia Issue: Volume 20:Number 4(2014:Jul.) Page Start: 593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗